In this week’s Clinical Pathway Blog, we share articles that show a unified (and global) response to the Cancer Moonshot, how IT is helping to treat cancer, and improvements in access to cancer health insurance coverage and treatment. OPeN, a Data-Sharing Initiative, Announced Ahead of the Cancer Moonshot Summit This article from AJMC.com expands on […]
ASCO releases a policy statement & recommendations for clinical pathways in oncology & nearly 50% of phase II and III trial sites missed enrollment targets.
This week in health care trends, our oncology clinical pathways spotlight includes a social network for clinical trial super responders, rising ACA premium rates, and thoughts on oncology reimbursement models.
U.S. Supreme Court rules 6-3 to uphold federal Obamacare subsidies for millions of Americans, and ASCO releases its long awaited Cancer Value Framework.
This week in healthcare, national survey finds cancer center advertisements frequently target people’s desire for miracles while rarely mentioning palliative care, and an estimated 576,000 Americans used medicines that cost more than $50,000, according to analysis by Express Scripts.
This week in health care trends, our oncology clinical pathways spotlight includes an expert panel’s discussion of pathways and payment reform and data about the impact of integrated delivery networks (IDNs) on drug selection and oncologist behavior.
This week in health care trends, our oncology clinical pathways spotlight includes the effects of oncology consolidation on patient access, the struggle between pathways and innovation, and finding the golden mean in attempting to measure quality.
This week in healthcare, Tennessee Oncology, BCBS-Tennessee and Via Oncology launch a pilot oncology clinical pathways program designed to provide better patient outcomes and lower costs, and CMS announced ACA enrollment extension period for Americans who may face penalties in 2015.
This week in health care trends, our spotlight on oncology clinical pathways includes updates about the immunotherapy debate, the impact of lower investment on innovation, a tool that compares in-network pricing, and high-cost drugs being put in a specialty tier.
HCA to Use Genomic Patient EHR Info to Recommend Targeted Therapies and ASCO Recommendations for Survivorship Care Plans
This week in healthcare, Hospital Corporation of America embarks on a widespread molecular profiling plan, and ASCO releases recommendations about survivorship care plans, Medicaid reform, and chemotherapy-induced peripheral neuropathy.
This week in healthcare, ASCO joins the comparative effectiveness research discussion with payers and Express Scripts announces their intentions to begin influencing the cancer drug market in 2016.
This week in healthcare, the New York Times compares U.S. and European drug costs and Express Scripts advocates for earlier involvement in the decision-making process to lower oncology drug costs.
Flatiron and NCCN Announce Cancer Quality and Outcomes Partnership and FDA Panel Recommends Approval of First Generic Biologic Drug
An FDA panel approves the first U.S. generic biologic drug and a study finds that if ACA subsidies were rescinded millions of Americans would lose coverage.
This week in healthcare, researchers dig into physician perceptions of payment reform, Kaiser opens clinics in Target stores, and analysts predict major healthcare trends of 2015.
U.S. Drug Prices May Rise 12% and Express Scripts Will Exclude 66 Brand Name Drugs from 2015 Formulary
This week in healthcare, Kaiser predicts drug prices will rise 12% and what will the Republican election wins mean for healthcare reform and the ACA?
Genentech Narrows Distribution Channel for Oncology Drugs and Soaring Generic Drug Prices Challenge Stakeholders
This week in healthcare, HHS admits its ACA enrollment numbers were inflated, oncology clinical pathways lead to cost savings and generic drug prices are “wreaking havoc.”